ArticleOncogene2000
RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 87 citations in OpenAlex.
- Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology.Acta neuropathologica communications · 2022Article
- RET kinase inhibitors forTherapeutic advances in medical oncology · 2022Review
- Development of an RNA sequencing panel to detect gene fusions in thyroid cancer.Genomics & informatics · 2021Article
- Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.Journal of cancer research and clinical oncology · 2021Review
- Review
- Zika virus increases mind bomb 1 levels, causing degradation of pericentriolar material 1 (PCM1) and dispersion of PCM1-containing granules from the centrosome.The Journal of biological chemistry · 2019Article
- Review
- Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations.Oncotarget · 2019Article
- Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review.Frontiers in physiology · 2019Review
- Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.Molecular cancer · 2018Review
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Nature reviews. Clinical oncology · 2018Review
- Mechanisms of receptor tyrosine kinase activation in cancer.Molecular cancer · 2018Review
- The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.OncoTargets and therapy · 2018Article
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.Nature reviews. Endocrinology · 2016Review
- Article
- Tyrosine kinase gene rearrangements in epithelial malignancies.Nature reviews. Cancer · 2013Review
- Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model.Carcinogenesis · 2013Article
- An image-based multi-label human protein subcellular localization predictor (iLocator) reveals protein mislocalizations in cancer tissues.Bioinformatics (Oxford, England) · 2013Article
- Article
- Molecular genetics and diagnosis of thyroid cancer.Nature reviews. Endocrinology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10 : 17 translocation. We previously developed a dual-color FISH test to detect these RET rearrangements in interphase nuclei of thyroid lesions. This approach allowed us to detect a novel translocation involving the RET region, which was not detectable by RT - PCR with specific primers for known rearrangements. A combination of RT - PCR and RACE analyses finally led to the identification of the fusion gene, which involves the 5' portion of PCM-1, a gene coding for a centrosomal protein with distinct cell cycle distribution, and the RET tyrosine kinase (TK) domain. FISH analysis confirmed the chromosomal localization of PCM-1 on chromosome 8p21-22, a region commonly deleted in several tumors. Immunohistochemistry, using an antibody specific for the C-terminal portion of PCM-1 showed that the protein level is drastically decreased and its subcellular localization is altered in thyroid tumor tissue with respect to normal thyroid. However, heterozygosity is retained for seven microsatellite markers in the 8p21-22 region, suggesting that the non-rearranged PCM-1 allele is not lost and that the translocation is balanced. Oncogene (2000) 19, 4236 - 4242
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.